Mersana reports updated Phase I data for XMT-1522 in HER2-expressing cancers

Mersana Therapeutics Inc. (NASDAQ:MRSN) reported data from 13 evaluable patients with advanced HER2-expressing breast, gastric or non-small cell

Read the full 186 word article

User Sign In